345 related articles for article (PubMed ID: 31628698)
1. Efficacy and safety of cariprazine in bipolar I depression: A double-blind, placebo-controlled phase 3 study.
Earley WR; Burgess MV; Khan B; Rekeda L; Suppes T; Tohen M; Calabrese JR
Bipolar Disord; 2020 Jun; 22(4):372-384. PubMed ID: 31628698
[TBL] [Abstract][Full Text] [Related]
2. Cariprazine Treatment of Bipolar Depression: A Randomized Double-Blind Placebo-Controlled Phase 3 Study.
Earley W; Burgess MV; Rekeda L; Dickinson R; Szatmári B; Németh G; McIntyre RS; Sachs GS; Yatham LN
Am J Psychiatry; 2019 Jun; 176(6):439-448. PubMed ID: 30845817
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial.
Yatham LN; Vieta E; Earley W
Int Clin Psychopharmacol; 2020 May; 35(3):147-156. PubMed ID: 32058426
[TBL] [Abstract][Full Text] [Related]
4. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
Earley WR; Guo H; Németh G; Harsányi J; Thase ME
Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
[TBL] [Abstract][Full Text] [Related]
5. An 8-Week Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Cariprazine in Patients With Bipolar I Depression.
Durgam S; Earley W; Lipschitz A; Guo H; Laszlovszky I; Németh G; Vieta E; Calabrese JR; Yatham LN
Am J Psychiatry; 2016 Mar; 173(3):271-81. PubMed ID: 26541814
[TBL] [Abstract][Full Text] [Related]
6. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial.
Sachs GS; Greenberg WM; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Affect Disord; 2015 Mar; 174():296-302. PubMed ID: 25532076
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Bipolar Disord; 2015 Feb; 17(1):63-75. PubMed ID: 25056368
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of low- and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study.
Calabrese JR; Keck PE; Starace A; Lu K; Ruth A; Laszlovszky I; Németh G; Durgam S
J Clin Psychiatry; 2015 Mar; 76(3):284-92. PubMed ID: 25562205
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
[TBL] [Abstract][Full Text] [Related]
10. Cariprazine for the treatment of bipolar mania with mixed features: A post hoc pooled analysis of 3 trials.
McIntyre RS; Masand PS; Earley W; Patel M
J Affect Disord; 2019 Oct; 257():600-606. PubMed ID: 31344528
[TBL] [Abstract][Full Text] [Related]
11. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial.
Durgam S; Starace A; Li D; Migliore R; Ruth A; Németh G; Laszlovszky I
Schizophr Res; 2014 Feb; 152(2-3):450-7. PubMed ID: 24412468
[TBL] [Abstract][Full Text] [Related]
12. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial.
Durgam S; Cutler AJ; Lu K; Migliore R; Ruth A; Laszlovszky I; Németh G; Meltzer HY
J Clin Psychiatry; 2015 Dec; 76(12):e1574-82. PubMed ID: 26717533
[TBL] [Abstract][Full Text] [Related]
13. Broad Efficacy of Cariprazine on Depressive Symptoms in Bipolar Disorder and the Clinical Implications.
Yatham LN; Vieta E; McIntyre RS; Jain R; Patel M; Earley W
Prim Care Companion CNS Disord; 2020 Sep; 22(5):. PubMed ID: 32942346
[TBL] [Abstract][Full Text] [Related]
14. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?
Citrome L
Int J Clin Pract; 2019 Oct; 73(10):e13397. PubMed ID: 31355510
[TBL] [Abstract][Full Text] [Related]
15. Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II/III studies.
Earley W; Durgam S; Lu K; Debelle M; Laszlovszky I; Vieta E; Yatham LN
J Affect Disord; 2017 Jun; 215():205-212. PubMed ID: 28343051
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Fava M; Durgam S; Earley W; Lu K; Hayes R; Laszlovszky I; Németh G
Int Clin Psychopharmacol; 2018 Nov; 33(6):312-321. PubMed ID: 30045066
[TBL] [Abstract][Full Text] [Related]
17. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies.
McIntyre RS; Suppes T; Earley W; Patel M; Stahl SM
CNS Spectr; 2020 Aug; 25(4):502-510. PubMed ID: 31576791
[TBL] [Abstract][Full Text] [Related]
18. The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study.
Ketter TA; Sachs GS; Durgam S; Lu K; Starace A; Laszlovszky I; Németh G
J Affect Disord; 2018 Jan; 225():350-356. PubMed ID: 28843918
[TBL] [Abstract][Full Text] [Related]
19. Adjunctive Cariprazine for the Treatment of Patients With Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study.
Sachs GS; Yeung PP; Rekeda L; Khan A; Adams JL; Fava M
Am J Psychiatry; 2023 Mar; 180(3):241-251. PubMed ID: 36789515
[TBL] [Abstract][Full Text] [Related]
20. Cariprazine for the Adjunctive Treatment of Major Depressive Disorder in Patients With Inadequate Response to Antidepressant Therapy: Results of a Randomized, Double-Blind, Placebo-Controlled Study.
Riesenberg R; Yeung PP; Rekeda L; Sachs GS; Kerolous M; Fava M
J Clin Psychiatry; 2023 Aug; 84(5):. PubMed ID: 37585254
[No Abstract] [Full Text] [Related]
[Next] [New Search]
